Fibrosis Associated Protein Inhibitor (FAPI) Radiotracer-based Imaging to Identify Fibrotic Intestinal Crohn's Disease

Not yet recruiting

• Conditions: Crohn Disease

• Registration Number: NCT07152431
• Lead Sponsor: University of Edinburgh

Brief Summary

Crohn's Disease (CD) is a chronic inflammatory condition that can affect any part of the intestine and currently has no cure. It affects 6.8 million people worldwide with UK healthcare costs in excess of £1 billion per year. Recent data suggests that the despite significant progress in treatments over the last 2 decades to help control disease, upto half of patients still develop progressive bowel scarring that require surgery and upto 70% needing surgery within 10-20 years from diagnosis. Unfortunately this is not a cure and some still require repeat surgery. These features have a devastating impact on an individual including education, work and social life. All our current treatments focus on resolving inflammation but there are no treatments targeting fibrosis, its activity and its progression. A major hurdle in our progress towards anti-fibrotic treatments and advancing care in CD has been our inability to identify bowel scarring accurately using non-invasive tests; this being critical in developing new treatments that prevent permanent bowel damage.

We are also unable to identify early stage scarring (fibrosis) and once established we are unable to differentiate between different stages of scarring severity.

We aim to investigate a novel method that can identify early scarring and track progressive bowel damage by tracking cells that cause fibrosis. In this study we will use a 'dye', also known as fibrosis associated protein inhibitor (FAPI), that tracks scarring and its activity in the intestine. The presence and amount of FAPI within an area of scarring can be detected using our current imaging tests (positron emission tomography and Computer Tomography imaging: PET/CT). If successful, this study will be the first method for detecting scarring activity in CD and have the potential to revolutionise care for this condition and facilitate new drug development to halt the processing of scarring (fibrosis) and improve the outcomes for patients with CD.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-08-25
• Study First Submitted QC: 2025-08-25
• Last Update Submitted: 2025-08-25
• Study Start: 2025-09-01
• Study First Posted: 2025-09-03
• Last Update Posted: 2025-09-03
• Primary Completion: 2028-08-01
• Study Completion: 2028-08-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Crohn's disease with ileal involvement (including those with disease recurrence in the neo-terminal ileum) due to commence biologics.

Exclusion Criteria

• Inability or unwilling to give informed consent.

  • History of claustrophobia or feeling of inability to tolerate supine position for the PET/MRI or PET/CT scans.
  • Impaired renal function with eGFR of <30 mL/min/1.73m2
  • Women who are pregnant or breastfeeding. Pregnancy test will be performed in all women of childbearing age
  • Contrast allergy
  • Contraindication to MRI (e.g. metallic implant or severe claustrophobia)
  • Significant mental health conditions that will impair the ability to consent or affect their ability to take part in the study
  • Patients with colonic disease only with no ileal or small bowel involvement.
  • Contraindications (Glaucoma and/or ischaemic heart disease) or allergy (eg:

anaphylaxis) to buscopan use.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fibrosis activity	36 months	To establish and quantify the intestinal fibrosis activity in patients with active fibrostenosing Crohn's disease phenotype (Montreal B2) and assess its utility in predicting fibrosis progression over time